| Symbol | CSPHF |
|---|---|
| Name | CSTONE PHARMACEUTICALS |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 0000 China 1000 Zhangheng Road, Building 25 Pudong New District |
| Telephone | ir@cstonepharma.com |
| Fax | — |
| — | |
| Website | http://www.cstonepharma.com/en/ |
| Incorporation | KY |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: Hong Kong Stock Exchange |
| CIK | — |
| Description | CStone Pharmaceuticals (HKEX:2616) is a biopharmaceutical company focused on developing and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, CStone has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. Currently, 5 late-stage candidates are at pivotal trials. With an experienced team, a rich pipeline, a robust clinical development-driven business model and substantial funding, CStones vision is to become globally recognized as a leading Chinese biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide. Additional info from OTC: |
No news found.